<SEC-DOCUMENT>0001193125-26-174330-index.html : 20260423
<SEC-HEADER>0001193125-26-174330.hdr.sgml : 20260423
<ACCEPTANCE-DATETIME>20260423200150
ACCESSION NUMBER:		0001193125-26-174330
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20260423
DATE AS OF CHANGE:		20260423

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Kailera Therapeutics, Inc.
		CENTRAL INDEX KEY:			0002096997
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-95629
		FILM NUMBER:		26890128

	BUSINESS ADDRESS:	
		STREET 1:		180 THIRD AVENUE
		STREET 2:		4TH FLOOR
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451
		BUSINESS PHONE:		508-440-9475

	MAIL ADDRESS:	
		STREET 1:		180 THIRD AVENUE
		STREET 2:		4TH FLOOR
		CITY:			WALTHAM
		STATE:			MA
		ZIP:			02451

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			BCLS Fund IV Investments, L.P.
		CENTRAL INDEX KEY:			0002015454
		ORGANIZATION NAME:           	
		EIN:				933190582
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D

	BUSINESS ADDRESS:	
		STREET 1:		200 CLARENDON STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		6175162000

	MAIL ADDRESS:	
		STREET 1:		200 CLARENDON STREET
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
Document 1 - file: primary_doc.html

Document 1 - RAW XML: primary_doc.xml

</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.B
<SEQUENCE>2
<FILENAME>ck0000000000-ex99_b.pdf
<DESCRIPTION>EX-99.B
<TEXT>
Document 2 - file: ck0000000000-ex99_b.pdf

</DOCUMENT>
</SEC-DOCUMENT>